Pseudomonas meningitis during vedolizumab therapy for Crohn's disease

American Journal of Gastroenterology

Volumn 110, Issue 11, 2015, Pages 1631-1632

  Boland, Brigid S ^a   Dulai, Parambir S ^a   Chang, Michael ^a   Sandborn, William J ^a   Levesque, Barrett G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMPICILLIN; AZATHIOPRINE; BUDESONIDE; CEFEPIME; CERTOLIZUMAB PEGOL; GLUCOSE; MEPREDNISONE; VANCOMYCIN; VEDOLIZUMAB; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ABDOMINAL TENDERNESS; ADULT; BACTERIUM CULTURE; CASE REPORT; COLONOSCOPY; CROHN DISEASE; DIARRHEA; DISEASE ACTIVITY; DRUG INFUSION; EMERGENCY WARD; FEMALE; FEVER; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; LETTER; LEUKOCYTE COUNT; LUMBAR PUNCTURE; MENINGITIS; PHOTOPHOBIA; PRIORITY JOURNAL; PSEUDOMONAS STUTZERI; RIGIDITY; TACHYCARDIA; TERMINAL ILEUM; TREATMENT DURATION; YOUNG ADULT; COMPLICATION; MENINGITIS, BACTERIAL; PSEUDOMONAS INFECTION;

ANTIBODIES, MONOCLONAL, HUMANIZED; CROHN DISEASE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MENINGITIS, BACTERIAL; PSEUDOMONAS INFECTIONS; PSEUDOMONAS STUTZERI; YOUNG ADULT;

EID: 84948773480     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2015.326     Document Type: Letter

References (8)

1. Sandborn WJ, Feagan BG, Rutgeerts P et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013; 369: 711-21
2. Dulai PS, Th ompson KD, Blunt HB et al. Risks of serious infection or lymphoma with antitumor necrosis factor therapy for pediatric infl ammatory bowel disease: a systematic review. Clin Gastroenterol Hepatol 2014; 12: 1443-51
3. Takeda Pharmaceuticals U.S.A. Inc. Vedolizumab for the treatment of ulcerative colitis and Crohn's disease. In: Briefi ng document for the joint meeting of the gastrointestinal drugs advisory committee and drug safety and risk management advisory committee. Deerfi eld, IL, USA, 9 December; 2013
4. Ramaswamy V, Cresence VM, Rejitha JS et al. Listeria: review of epidemiology and patho genesis. J Microbiol Immunol Infect 2007; 40: 4-13
5. Carvalho-Assef AP, Gomes MZ, Silva AR et al. IMP-16 in Pseudomonas putida and Pseudomonas stutzeri: potential reservoirs of multidrug resistance. J Med Microbiol 2010; 59: 1130-1
6. Sunbul M, Zivalioglu M, Tasdelen Fisgin N. Community-Acquired Pseudomonas stutzeri meningitis in an immunocompetent patient. Mikrobiyol Bul 2009; 43: 159-62
7. Keys TF, Melton LJ 3rd, Maker MD et al. A suspected hospital outbreak of pseudobacteremia due to Pseudomonas stutzeri. J Infect Dis 1983; 147: 489-93
8. Reisler RB, Blumberg H. Community-Acquired Pseudomonas stutzeri vertebral osteomyelitis in a previously healthy patient: case report and review. Clin Infect Dis 1999; 29: 667-9